Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
03/2005
03/02/2005EP1509501A1 1-(aminoalkyl)-3-sulfonylindole and -indazole derivatives as 5-hydroxytryptamine-6 ligands
03/02/2005EP1509499A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
03/02/2005EP1509224A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
03/02/2005EP1509218A1 Peptide deformylase inhibitors
03/02/2005EP1282084B9 Method for preparing pyrimidone derivatives with antifungal activity
03/02/2005EP1244649B1 Cyclic amp-specific phosphodiesterase inhibitors
03/02/2005EP1042279B1 Substituted beta-alanines
03/02/2005EP1014976B1 Novel substituted imidazole compounds
03/02/2005EP0871448B1 Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase
03/02/2005CN1589270A Indole-2-formamide compounds as factor Xa inhibitors
03/02/2005CN1589260A Heterocyclic compounds and methods of use thereof
03/02/2005CN1589143A Method for cancer therapy
03/02/2005CN1191239C Pyrazole derivatives for the treatment of viral diseases
03/01/2005US6861446 C7 heterosubstituted acetate taxane compositions
03/01/2005US6861440 Antidiabetic agents
03/01/2005US6861432 Piperazine derivatives that destabilize androgen receptors
03/01/2005US6861418 Modulating protein kinase signal transduction; anticancer agents
03/01/2005US6861417 Such as 2-(4-fluorophenyl)-3-(pyridin-4-yl)pyrazine for treating cytokine mediated diseases such as psoriatic arthritis
03/01/2005US6861389 Substituted 2-amino-1,3,5-triazines, their preparation, and their use as herbicides and plant growth regulators
03/01/2005US6861162 Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
02/2005
02/24/2005WO2005017190A2 Mitotic kinesin inhibitors
02/24/2005WO2005016920A1 Pyrrole compositions useful as inhibitors of c-met
02/24/2005WO2005016918A2 Heterocyclic n-aryl carboxamides as cytokine inhibitors
02/24/2005WO2005016914A1 Chemical compounds
02/24/2005WO2005016897A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
02/24/2005WO2005016896A1 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators
02/24/2005WO2005016894A1 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
02/24/2005WO2005016893A2 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
02/24/2005WO2005016892A1 Gabanergic modulators
02/24/2005WO2005016888A1 Probe for diseases wth amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
02/24/2005WO2005016883A2 Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
02/24/2005WO2005016879A2 Cyclic pyrazinoylguanidine sodium channel blockers
02/24/2005WO2005016876A2 Cyclic amine bace-1 inhibitors having a benzamide substituent
02/24/2005WO2005016875A2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
02/24/2005WO2005016862A1 Substituted arylalkanoic acid derivative and use thereof
02/24/2005WO2005016384A1 Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
02/24/2005WO2005016340A1 Furanone derivatives
02/24/2005WO2005016326A2 Analogs of thalidomide as potential angiogenesis inhibitors
02/24/2005WO2005016000A1 Derivatives of cyclic quinone and uses thereof
02/24/2005WO2005005393A3 Cck-1 receptor modulators
02/24/2005WO2004094395A3 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
02/24/2005WO2004093789A3 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
02/24/2005US20050043543 Benzotriazole/HALS molecular combinations and compositions stabilized therewith
02/24/2005US20050043390 Viricides against herpes virus
02/24/2005US20050043388 Therapy, prevention of metabolism disorders; insulin resistance; antidiabetic agents; hypoglycemic agents; anticholesterol agents; obesity; polycystic ovarian syndrome
02/24/2005US20050043385 Hydroxyalkylindole derivatives as anticancer agent
02/24/2005US20050043381 Aminopyrazole compounds
02/24/2005US20050043364 Novel pyrrole-based HMG-CoA reductase inhibitors
02/24/2005US20050043354 Substance P antagonist
02/24/2005US20050043348 Phenyl-substituted imidazopyridines
02/24/2005US20050043337 Selective beta3 adrenergic agonists
02/24/2005US20050043336 Quinazoline derivatives as antitumor agents
02/24/2005US20050043331 Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
02/24/2005US20050043330 Antiinflammation agents
02/24/2005US20050043317 Biaryl heterocyclic compounds and methods of making and using the same
02/24/2005US20050043315 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
02/24/2005US20050043314 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
02/24/2005US20050043313 1-(phenylaminocarbonylmethyl)-3-alkylamino-5,6-disubstituted-2-pyazinones; serine protease inhibitors; anticoagulants; coronary artery and cerebrovascular diseases
02/24/2005US20050043310 Such as (R)-4-bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-quinoxaline-sulfonylamino)-benzamide via sulfonylation; cholecystokinin receptor modulators
02/24/2005US20050043305 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
02/24/2005US20050043302 New indole derivatives as factor Xa inhibitors
02/24/2005US20050043299 Inhibitors of dipeptidyl peptidase iv
02/24/2005US20050043292 eg S)-[5-amino-6-oxo-6-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-hexyl-carbamic acid benzylester; Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy
02/24/2005US20050043290 for treating neurodegenerative disease such as Alzheimer's disease
02/24/2005US20050042407 containing a cyanovinylene group; can be written on or read by blue light, preferably laser light
02/24/2005US20050039268 Use of dicatonic compounds for dyeing human keratinous fibres and compositions containing the same
02/24/2005DE102004010545A1 Pyrazoline Pyrazolines
02/24/2005CA2743534A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
02/24/2005CA2536470A1 Pyrrole compositions useful as inhibitors of c-met
02/24/2005CA2535665A1 Substituted arylalkanoic acid derivative and use thereof
02/24/2005CA2535406A1 Gabanergic modulators
02/24/2005CA2534950A1 Cyclic amine bace-1 inhibitors having a benzamide substituent
02/24/2005CA2534887A1 Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
02/24/2005CA2534729A1 Mitotic kinesin inhibitors
02/24/2005CA2529767A1 Aripiprazole and haloperidol pamoate salts
02/24/2005CA2518774A1 Heterocyclic n-aryl carboxamides as cytokine inhibitors
02/24/2005CA2500358A1 Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles
02/23/2005EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
02/23/2005EP1507775A1 Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
02/23/2005EP1507769A1 Copper-catalysed ligation of azides and acetylenes
02/23/2005EP1507535A1 Pyrimidine-2,4,6-trione metallo-proteinase inhibitors
02/23/2005EP1507528A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
02/23/2005EP1226128B1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
02/23/2005EP0947507B1 Novel tetrahydrobenzindolone derivatives
02/23/2005CN1585768A Pyrazole derivatives as psychopharmaceuticals
02/23/2005CN1585763A Piperidine derivatives and their use as modulators of chemokine receptor activity especially CCR5
02/23/2005CN1585754A Quinazoline derivatives as antitumor agents
02/23/2005CN1585752A 4, 4-difluoro-1, 2, 3, 4-tetrahydro-5H-1-benzazepine derivatives or salts thereof
02/23/2005CN1585749A Cannabinoid receptor ligands
02/23/2005CN1585748A NK1 antagonists
02/23/2005CN1585747A Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1
02/23/2005CN1585643A Benzotriazepines as gastrin and cholecystokinin receptor ligands
02/23/2005CN1585641A Hydrazono-malonitriles
02/23/2005CN1190432C Piperazing derivatives as 5-HTIB antagonists
02/23/2005CN1190423C Heteroycle derivatives and drugs
02/23/2005CN1190420C Non-peptide neomatal vascularization inhibitor
02/22/2005US6858740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
02/22/2005US6858641 Substituted indolinones
02/22/2005US6858638 Substituted indazoles, compositions containing them, method of production and use
02/22/2005US6858636 Angiotensin II antagonists for treating cardiovascular disorders, hypertension, congestive heart failure and glaucoma.
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 626